Abstract:Although several cell-based therapies have received FDA approval, and others are showing promising results, scalable, and quality-driven reproducible manufacturing of therapeutic cells at a lower cost remains challenging. Challenges include starting material and patient variability, limited understanding of manufacturing process parameter effects on quality, complex supply chain logistics, and lack of predictive, well-understood product quality attributes. These issues can manifest as increased production costs, longer production times, greater batch-to-batch variability, and lower overall yield of viable, high-quality cells. The lack of data-driven insights and decision-making in cell manufacturing and delivery is an underlying commonality behind all these problems. Data collection and analytics from discovery, preclinical and clinical research, process development, and product manufacturing have not been sufficiently utilized to develop a "systems" understanding and identify actionable controls. Experience from other industries shows that data science and analytics can drive technological innovations and manufacturing optimization, leading to improved consistency, reduced risk, and lower cost. The cell therapy manufacturing industry will benefit from implementing data science tools, such as data-driven modeling, data management and mining, AI, and machine learning. The integration of data-driven predictive capabilities into cell therapy manufacturing, such as predicting product quality and clinical outcomes based on manufacturing data, or ensuring robustness and reliability using data-driven supply-chain modeling could enable more precise and efficient production processes and lead to better patient access and outcomes. In this review, we introduce some of the relevant computational and data science tools and how they are being or can be implemented in the cell therapy manufacturing workflow. We also identify areas where innovative approaches are required to address challenges and opportunities specific to the cell therapy industry. We conclude that interfacing data science throughout a cell therapy product lifecycle, developing data-driven manufacturing workflow, designing better data collection tools and algorithms, using data analytics and AI-based methods to better understand critical quality attributes and critical-process parameters, and training the appropriate workforce will be critical for overcoming current industry and regulatory barriers and accelerating clinical translation.

Integration of Systems Biology in Cell Line and Process Development for Biopharmaceutical Manufacturing

1H NMR-based Process Understanding and Biochemical Marker Identification Methodology for Monitoring CHO Cell Culture Process During Commercial-Scale Manufacturing

Recent advances in technology supporting biopharmaceutical production from mammalian cells

From Chemostats to High-Density Perfusion: the Progression of Continuous Mammalian Cell Cultivation

Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing

Cell-culture process optimization via model-based predictions of metabolism and protein glycosylation

Quality cell therapy manufacturing by design

Development and Qualification of a Scale-Down Mammalian Cell Culture Model and Application in Design Space Development by Definitive Screening Design

An Integrated Approach toward the Biomanufacturing of Engineered Cell Therapy Products in a Stirred-Suspension Bioreactor

From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies

CHO cell productivity improvement by genome-scale modeling and pathway analysis: Application to feed supplements

Interfacing data science with cell therapy manufacturing: where we are and where we need to be

Product quality considerations for mammalian cell culture process development and manufacturing

High‐throughput and automation advances for accelerating single‐cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production

Toward microfluidic continuous-flow and intelligent downstream processing of biopharmaceuticals

Applications of Machine Learning in Biopharmaceutical Process Development and Manufacturing: Current Trends, Challenges, and Opportunities

Microbial technologies for biotherapeutics production: Key tools for advanced biopharmaceutical process development and control

Multi-omic characterization of antibody-producing CHO cell lines elucidates metabolic reprogramming and nutrient uptake bottlenecks

Upstream process intensification and continuous manufacturing

Towards a widespread adoption of metabolic modeling tools in biopharmaceutical industry: a process systems biology engineering perspective

Stem Cell Culture Engineering – Process Scale Up and Beyond